2型糖尿病中非白蛋白尿性慢性肾脏病肾功能快速下降、全因死亡及主要心血管事件风险
研究纳入ACCORD试验中10,185例2型糖尿病参与者,按基线白蛋白尿和eGFR分为无CKD、仅白蛋白尿、仅eGFR降低(非白蛋白尿性CKD)及两者并存(白蛋白尿性CKD)四组。结果显示非白蛋白尿性CKD的eGFR下降速率慢于其他组,但死亡和主要心血管事件风险仍高于无CKD者;ESKD风险未增加。
要点
- 非白蛋白尿性CKD的eGFR年下降速率为-0.60 mL/min/年,慢于无CKD者的-1.31 mL/min/年(P<0.001)。
- 非白蛋白尿性CKD的ESKD风险未增加(HR 0.76,95%CI 0.34–1.70),白蛋白尿性CKD风险最高(HR 4.52,95%CI 2.91–7.01)。
- 非白蛋白尿性CKD的死亡风险(HR 1.42,95%CI 1.14–1.78)和MACE风险(HR 1.44,95%CI 1.13–1.84)仍高于无CKD者。
核心结论
- 非白蛋白尿性CKD患者的eGFR下降速率慢于其他任何组,但其死亡和MACE风险仍高于无CKD者。
研究设计与样本
- 研究纳入ACCORD试验中10,185例2型糖尿病参与者,根据基线白蛋白尿和eGFR分为无CKD、仅白蛋白尿(白蛋白尿性非CKD)、仅eGFR降低(非白蛋白尿性CKD)及两者并存(白蛋白尿性CKD)四组。
主要发现
- 无CKD组和非白蛋白尿性CKD组的eGFR下降速率分别为-1.31和-0.60 mL/min/年(P<0.001)。
- 在竞争风险分析中(以无CKD为参照),非白蛋白尿性CKD的ESKD风险未增加(HR 0.76,95%CI 0.34–1.70),白蛋白尿性CKD风险最高(HR 4.52,95%CI 2.91–7.01)。
- 在校正Cox模型中,白蛋白尿性CKD的死亡和MACE风险最高(HR分别为2.38,95%CI 1.92–2.90和2.37,95%CI 1.89–2.97)。
- 白蛋白尿性非CKD的死亡和MACE风险(HR分别为1.82,95%CI 1.59–2.08和1.88,95%CI 1.63–2.16)高于非白蛋白尿性CKD(HR分别为1.42,95%CI 1.14–1.78和1.44,95%CI 1.13–1.84)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate the rate of progression of nonalbuminuric chronic kidney disease (CKD) to end-stage kidney disease (ESKD) or death or major cardiovascular events (MACE) compared with albuminuric and nonalbuminuric phenotypes. RESEARCH DESIGN AND METHODS: We included 10,185 participants with type 2 diabetes enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Based on baseline albuminuria and estimated glomerular filtration rate (eGFR), participants were classified as having no kidney disease (no CKD), albuminuria only (albuminuric non-CKD), reduced eGFR only (nonalbuminuric CKD), or both albuminuria and reduced eGFR (albuminuric CKD). The rate of eGFR decline and hazard ratios (HRs) for ESKD or death or MACE were calculated. RESULTS: For individuals with no CKD and those with nonalbuminuric CKD, the rates of eGFR decline were -1.31 and -0.60 mL/min/year, respectively (P < 0.001). In competing-risks analysis (no CKD as the reference), HRs for ESKD indicated no increased risk for nonalbuminuric CKD (0.76 [95% CI 0.34, 1.70]) and greatest risk for albuminuric CKD (4.52 [2.91, 7.01]). In adjusted Cox models, HRs for death and MACE were highest for albumuniuric CKD (2.38 [1.92, 2.90] and 2.37 [1.89, 2.97], respectively) and were higher for albuminuric non-CKD (1.82 [1.59, 2.08] and 1.88 [1.63, 2.16], respectively) than for those with nonalbuminuric CKD (1.42 [1.14, 1.78] and 1.44 [1.13, 1.84], respectively). CONCLUSIONS: Those with nonalbuminuric CKD showed a slower rate of decline in eGFR than did any other group; however, these individuals still carry a greater risk for death and MACE than do those with no CKD.
引用
- Buyadaa O, Magliano DJ, Salim A, et al. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care. 2019. PMID: 31796570. doi:10.2337/dc19-1438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。